breakthrough pain

Type: Keyphrase
Name: breakthrough pain
First reported Apr 14 2014 - Updated Apr 14 2014 - 2 reports

Human medicines European public assessment report (EPAR): Instanyl, fentanyl, Revision: 8, Authorised

This is a summary of the European public assessment report (EPAR) for Instanyl. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its ... [Published European Medicines Agency - Apr 14 2014]
First reported Apr 07 2014 - Updated Apr 07 2014 - 1 reports

Questions, questions, questions

Hi all,Short story: I fell on ice in Jan 2013 and landed on my left arm. It didn't hurt that much so I treated it with ice and ibuprofen. One month later the pain got worse so I went to family doc who got x-rays which showed nothing. Then we tried to ... [Published HealthBoards - Apr 07 2014]
First reported Apr 04 2014 - Updated Apr 04 2014 - 1 reports

New Analgesics Findings Reported from Seoul National University

(NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Analgesics. According to news reporting out of Seoul, South Korea, by NewsRx editors, research stated, "Palliative care physicians are accustomed ... [Published NewsRX - Apr 04 2014]
First reported Apr 02 2014 - Updated Apr 02 2014 - 1 reports

FG Xpress Releases Natural Pain Relief Solution

FG Xpress launches a new natural pain relief solution in the market. According to a release, the PowerStrips from FG Xpress is a pain relief product designed to take away all kinds of muscle pains naturally and safely. The product is formulated with key ... [Published Individual.com - Apr 02 2014]
First reported Mar 28 2014 - Updated Mar 29 2014 - 2 reports

FG Xpress launches new revolutionary natural pain relief solution for muscle pains

FG Xpress launches a new revolutionary natural pain relief solution in the market. The PowerStrips from FG Xpress is a pain relief product designed to take away all kinds of muscle pains naturally and safely. The product is formulated with key ingredients ... [Published News-Medical.Net - Mar 29 2014]
First reported Mar 28 2014 - Updated Mar 28 2014 - 1 reports

Update - no Suboxone for me just yet

As some of you know, the last 6 months or so I had been deciding on / planning for a switch from Methadone (120mg/day) to Suboxone. There were concerns about hyperalgesia, my high opiate tolerance, and how to treat my pain long term. Here is an upd ... [Published HealthBoards - Mar 28 2014]
Entities: Suboxone, Methadone, Opiate
First reported Mar 19 2014 - Updated Mar 19 2014 - 1 reports

Insys Therapeutics to Present at the 13th Annual Needham Healthcare Conference

PHOENIX, AZ -- (Marketwired) -- 03/19/14 -- Insys Therapeutics, Inc. (NASDAQ: INSY) today announced that the Company will present at the 13th Annual Needham Healthcare Conference on April 8 - 9, 2014 at the Westin Grand Central in New York City.Michael ... [Published FinanzNachrichten.de - Mar 19 2014]
First reported Mar 18 2014 - Updated Mar 18 2014 - 1 reports

Galena slumps after disclosing SEC inquiry

NEW YORK -- Shares of Galena Biopharma continued to skid Tuesday after the company said the Securities and Exchange Commission is investigating the company and an investor relations firm it hired in 2013.Galena said it is cooperating with the inquiry ... [Published CNBC - Mar 18 2014]
First reported Mar 14 2014 - Updated Mar 14 2014 - 2 reports

BioDelivery Sciences Provides Business Review and -2-

BDSI's pain franchise consists of three products, two of which utilize the patented BioErodible MucoAdhesive (BEMA) drug delivery technology. ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, E.U. (where it is marketed as BREAKYL) ... [Published Scottrade - Mar 14 2014]
First reported Mar 07 2014 - Updated Mar 07 2014 - 2 reports

Is Galena Following In The Footsteps Of Insys With Abstral?

By Cashpotato :On March 4, 2014, Insys ( INSY ) announced record sales of its drug Subsys. Subsys is the first and only sublingual spray for breakthrough cancer pain. Similarly, Abstral, by Galena ( GALE ), is the first and only fentanyl sublingual tablet ... [Published BioPortfolio - Mar 07 2014]
First reported Mar 03 2014 - Updated Mar 04 2014 - 2 reports

Galena Biopharma launches Galena Patient Services

Galena Biopharma has announced the launch of Galena Patient Services (GPS), a full-service support program designed to enhance patient access to commercial products offered by the company.Currently, Galena markets Abstral (fentanyl) sublingual tablets ... [Published Pharmaceutical Business Review - Mar 04 2014]
First reported Jan 29 2014 - Updated Jan 29 2014 - 2 reports

fentanyl patch and MS Contin ???

Could anyone tell me if it's ok to take MS Contin for breakthrough pain while using the fentanyl patch ... I had a very bad flair up and I take Hydrocodone 4 times a day and had to take more than 4 and now not enough to my next appointment .. I have some ... [Published HealthBoards - Jan 29 2014]

Quotes

...maceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx "s lead product candidate, Zalviso™, is designed to improve the management of moderate-to-severe acute pain in patients in the hospital setting by utilizing a high therapeutic index opioid, through a non-invasive delivery route via a pre-programmed patient-controlled analgesia device.  AcelRx has announced positive results from each of the three completed Phase 3 clinical trials for Zalviso, and has submitted an NDA to the FDA seeking approval for Zalviso in the treatment of moderate-to-severe acute pain in adult patients in the hospital setting.  AcelRx plans to initiate a Phase 3 clinical trial for ARX-04, a product candidate for the treatment of moderate-to-severe acute pain in a medically supervised setting, during the second half of 2014. The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development. For additional information about AcelRx" s clinical programs, please visit www.acelrx.com
The night RMO, when called at 11pm, noted "abdomen distended, no ascites, no localised tenderness or guarding, pressure on lower abdomen exacerbates distress" and concluded, "delirium due to opioid"
Our news journalists obtained a quote from the research from Seoul National University, "Although several formulations of fentanyl have... We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3."
...that will be dedicated solely to support the introduction of BUNAVAIL," said David Acheson, Vice President of Sales and Managed Markets for BDSI. "Leading this collaborative effort with Quintiles, BDSI will be in a position to build an experienced and highly committed sales force. Additionally, the added strength of Ashfield Market Access provides us critical access to trade and managed markets by tapping into the resources of individuals with significant experience and long-term relationships with payers. We believe the combined resources of Quintiles and Ashfield Market Access, along with our other partners, our internal commercial experience, and a well differentiated product in BUNAVAIL, will help support a strong introduction."

More Content

All (83) | News (61) | Reports (0) | Blogs (15) | Audio/Video (0) | Fact Sheets (0) | Press Releases (5)
sort by: Date | Relevance
Human medicines European public assessment repo... [Published European Medicines Agency - Apr 14 2014]
Human medicines European public assessment repo... [Published European Medicines Agency - Apr 14 2014]
Depomed : Announces Settlements with Two Gralis... [Published 4 Traders - Apr 14 2014]
Pain: An LTC rehab perspective [Published McKnight's Long Term Care News - Apr 11 2014]
AcelRx Pharmaceuticals Coverage Initiated at Je... [Published American Banking News - Stock Ratings - Apr 10 2014]
AcelRx Pharmaceuticals to Present at the 13th A... [Published Asian Hospital & Healthcare Management - Apr 08 2014]
Opioid-related constipation [Published Australian Doctor - Apr 08 2014]
Questions, questions, questions [Published HealthBoards - Apr 07 2014]
BioDelivery Sciences Announces Four BUNAVAIL Ab... [Published ADVFN India - Apr 07 2014]
Forum Post: Fighting a losing battle? [Published Macmillan Cancer Support - Apr 05 2014]
AcelRx Pharmaceuticals to Present at the 13th A... [Published Financial Services - Apr 04 2014]
AcelRx Pharmaceuticals to Present at the 13th A... [Published FinanzNachrichten.de - Apr 04 2014]
New Analgesics Findings Reported from Seoul Nat... [Published NewsRX - Apr 04 2014]
FG Xpress Releases Natural Pain Relief Solution [Published Individual.com - Apr 02 2014]
BioDelivery Sciences Announces Commercializatio... [Published Fierce CRO - Mar 31 2014]
Insys Therapeutics Completes Three-for-Two Stoc... [Published InvestorPoint.com - Mar 31 2014]
FG Xpress launches new revolutionary natural pa... [Published News-Medical.Net - Mar 29 2014]
A Revolutionary Natural Pain Relief Solution is... [Published TickerTech.com - Mar 28 2014]
Update - no Suboxone for me just yet [Published HealthBoards - Mar 28 2014]
An analysis of the variability of breakthrough ... [Published Oncology Report - Mar 27 2014]
BioDelivery Sciences Announces Commercializatio... [Published Michigan Live - Mar 27 2014]
Depomed A 'Turtle' Gaining In Specialty Pharma ... [Published Nasdaq - Mar 25 2014]
AcelRx Pharmaceuticals Appoints Timothy E. Morr... [Published TheStreet.com - Mar 25 2014]
ONLINE FIRST: New NCCN Guidelines for Periphera... [Published Oncology Times - Mar 21 2014]
Insys Therapeutics to Present at the 13th Annua... [Published FinanzNachrichten.de - Mar 19 2014]
Pain Management in Dementia [Published U.S.Pharmacist - Mar 19 2014]
Depomed Earns $10 Million Milestone for FDA App... [Published FirstWord Pharma - Mar 19 2014]
Alexza’s AZ-104 (Staccato® Loxapine) Phase 2a T... [Published Delphi Ventures - Mar 18 2014]
AcelRx Pharmaceuticals Given Consensus Recommen... [Published American Banking News - Mar 18 2014]
Galena slumps after disclosing SEC inquiry [Published CNBC - Mar 18 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Questions, questions, questions [Published HealthBoards - Apr 07 2014]
Hi all,Short story: I fell on ice in Jan 2013 and landed on my left arm. It didn't hurt that much so I treated it with ice and ibuprofen. One month later the pain got worse so I went to family doc who got x-rays which showed nothing. Then we tried to ...
Update - no Suboxone for me just yet [Published HealthBoards - Mar 28 2014]
As some of you know, the last 6 months or so I had been deciding on / planning for a switch from Methadone (120mg/day) to Suboxone. There were concerns about hyperalgesia, my high opiate tolerance, and how to treat my pain long term. Here is an upd ...
AcelRx Pharmaceuticals to Participate at the 26... [Published PR Newswire: General Business - Mar 07 2014]
REDWOOD CITY, Calif., March 7, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough ...
One week out from PTTD surgery. Pain questions? [Published HealthBoards - Mar 05 2014]
Hi all.I'm sorry I've been a bit absent and I hope that all of you are doing well in you various stages of recovery and rehab. I had my surgery a week ago monday, and I won't lie, the pain has been intense enough that I've spent much of that time in ...
AcelRx Pharmaceuticals to Hold Fourth Quarter a... [Published PR Newswire: Health - Feb 24 2014]
REDWOOD CITY, Calif., Feb. 24, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough ...
1 2 3

Press Releases

sort by: Date | Relevance
AcelRx Pharmaceuticals to Present at the 13th A... [Published Financial Services - Apr 04 2014]
AcelRx Pharmaceuticals Reports Fourth Quarter a... [Published Financial Services - Mar 03 2014]
Orexo announces the launch of Abstral® in Japan [Published GlobeNewswire: Acquisitions News - Dec 12 2013]
AcelRx Pharmaceuticals Reports Third Quarter 20... [Published PR Newswire - Nov 05 2013]
Depomed Announces the Launch of Lazanda® (fenta... [Published PR Newswire - Oct 28 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.